Endo Pharmaceuticals (Schizophernia Treatment) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Endo Pharmaceuticals (Schizophernia Treatment) General Information

Description

Medical formulation for treatment of schizophrenia. An implantable, six-month formulation of the atypical antipsychotic risperidone for treating schizophrenia and other serious psychiatric disorders.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Buildings and Property
Other Industries
Therapeutic Devices
Acquirer
Corporate Office
  • Simmonscourt Road, Ballsbridge
  • 1st Floor, Minerva House
  • Dublin 4
  • Ireland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Endo Pharmaceuticals (Schizophernia Treatment) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Endo Pharmaceuticals (Schizophernia Treatment)‘s full profile, request access.

Request a free trial

Endo Pharmaceuticals (Schizophernia Treatment) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Endo Pharmaceuticals (Schizophernia Treatment)‘s full profile, request access.

Request a free trial

Endo Pharmaceuticals (Schizophernia Treatment) FAQs

  • Where is Endo Pharmaceuticals (Schizophernia Treatment) headquartered?

    Endo Pharmaceuticals (Schizophernia Treatment) is headquartered in Dublin, Ireland.

  • What industry is Endo Pharmaceuticals (Schizophernia Treatment) in?

    Endo Pharmaceuticals (Schizophernia Treatment)’s primary industry is Buildings and Property.

  • Is Endo Pharmaceuticals (Schizophernia Treatment) a private or public company?

    Endo Pharmaceuticals (Schizophernia Treatment) is a Private company.

  • What is Endo Pharmaceuticals (Schizophernia Treatment)’s current revenue?

    The current revenue for Endo Pharmaceuticals (Schizophernia Treatment) is 000000.

  • Who are Endo Pharmaceuticals (Schizophernia Treatment)’s investors?

    Endo International has invested in Endo Pharmaceuticals (Schizophernia Treatment).

  • When was Endo Pharmaceuticals (Schizophernia Treatment) acquired?

    Endo Pharmaceuticals (Schizophernia Treatment) was acquired on 01-May-2015.

  • Who acquired Endo Pharmaceuticals (Schizophernia Treatment)?

    Endo Pharmaceuticals (Schizophernia Treatment) was acquired by Braeburn.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »